Aquestive Therapeutics, Inc. current report, 06 June 2022

Full document

Business Context and Reporting Period

Company: Aquestive Therapeutics, Inc. (AQST)
Filing Type: Form 8-K (Current Report)
Date of Report: June 6, 2022
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering.

Key Financial Metrics and Transaction Details

This filing details a capital raise rather than operational financial results. Key transaction metrics include:

  • Gross Proceeds: Approximately $8.5 million.
  • Net Proceeds: Approximately $7.8 million (after fees and expenses).
  • Securities Issued:
    • 4,850,000 shares of Common Stock.
    • Pre-funded warrants to purchase up to 4,000,000 shares.
    • Common Stock Warrants to purchase up to 8,850,000 shares.
  • Offering Prices:
    • $0.96 per Share and associated Warrant (public).
    • $0.9599 per Pre-Funded Warrant and associated Warrant.
    • $1.09 per Share and associated Warrant (Insider Securities).
  • Placement Agent Fees: 6.0% of gross proceeds from Shares and Pre-Funded Warrants (excluding Insider Securities) plus up to $50,000 in expense reimbursement.

Material Changes and Use of Proceeds

The filing does not report operational changes or comparative financial periods. The primary material change is the increase in equity capital and potential dilution from the issuance of new shares and warrants. The Company intends to use the net proceeds for general corporate purposes.

Guidance, Outlook, and Restrictions

  • Lock-up/Restriction: The Company agreed not to conduct any issuances of Common Stock or enter into variable rate transactions for 90 days following the closing of the offering.
  • Warrant Terms: Common Stock Warrants are exercisable six months after issuance and expire on the fifth anniversary. Pre-Funded Warrants are immediately exercisable at $0.0001.
  • Outlook: No specific operational guidance or revenue outlook is provided in this filing.

Investor Verification Checklist

  • Verify the final closing date and actual net proceeds received.
  • Review the impact of the 8,850,000 new warrants on future dilution.
  • Confirm the specific allocation of the $7.8 million net proceeds in subsequent filings.
  • Monitor the 90-day restriction period for any potential waivers or additional capital raises.